11:20 AM EDT, 05/15/2024 (MT Newswires) -- PharmaTher Holdings ( PHRRF ) , said Wednesday Sairyiyo Therapeutics, 49% owned by PharmaTher ( PHRRF ) and 51% owned by PharmaDrug ( LMLLF ) , submitted to the Australian Human Research Ethics Committee to review and potentially approve, a Phase 1 clinical study of Sairiyo's reformulated enteric coated version of orally bioavailable cepharanthine (PD-001) as a potential treatment for infectious diseases and oncology.

If approved, the Phase 1 study will be a first-in-human study of PD-001. Sairiyo subsidiary, Sairiyo Therapeutics Australia is the study sponsor.

The clinical study of PD-001 could earn Sairiyo a 43.5% Australian federal tax rebate. Upon completion of the study, Sairiyo will submit an Investigational New Drug application for PD-001 to the FDA for Phase 2 and Phase 3 clinical trials in the U.S.

Price: 0.23, Change: +0.01, Percent Change: +2.27